Breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic) under 20% or 1% oxygen conditions.

The main purpose of this project is to identify gene expression changes between treated breast cancer cells (w/ MBZ) vs. non-treated cells (w/o MBZ) under normal (20% O2) or hypoxic (1% O2) conditions. Preliminary analysis using iclue revealed that MBZ might behave similarly to HIF inhbitors so we hypothesize that MBZ might repress HIF-response under hypoxia. We have submitted three different cell lines: SUM159 (SM), MDA-MB-231 (MDA) and MCF7; MBZ treatment: 0uM of MBZ (0M or 0); 1uM MBZ (1M or 1); Oxygen conditions: 1% O2 - hypoxia (H); 20% O2 - normoxia (N). Breast cancer cell lines were treated either with 1 uM or 0 uM of MBZ under 20% or 1% oxygen